US OptionsDetailed Quotes
SVRA240719P1000
- 0.06
- 0.000.00%
15min DelayClose Jul 5 15:50 ET
0.00High0.00Low
0.06Open0.06Pre Close0 Volume1.23K Open Interest1.00Strike Price0.00Turnover525.79%IV78.78%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.0238Delta0.0125Gamma73.83Leverage Ratio-0.0091Theta-0.0001Rho-1.76Eff Leverage0.0005Vega
Savara Stock Discussion
Sign in to post a comment
$Savara(SVRA.US$ It had pretty great news this morning on trial meeting endpoint! And yet its seeing the largest single day drop since March of 2023! Hehehe. Sad
11
🫣
$Savara (SVRA.US)$ Oppenheimer analyst Francois Brisebois maintains $Savara (SVRA.US)$ with a buy rating, and adjusts the target price from $11 to $15.
According to TipRanks data, the analyst has a success rate of 34.1% and a total average return of -5.5% over the past year.
According to TipRanks data, the analyst has a success rate of 34.1% and a total average return of -5.5% over the past year.
1
$Savara(SVRA.US$ die 😂
1
$Savara(SVRA.US$ Really !!!!
1
$Savara(SVRA.US$ PAP is a rare lung disease caused by a buildup of proteins, fats, and other substances in the lungs’ air sacs (alveoli).
Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
The treatment difference between molgramostim and placebo for mean change from baseline to Week 24 in hemoglobin-adjusted percent predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) achieved statistical significance, with a change...
Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
The treatment difference between molgramostim and placebo for mean change from baseline to Week 24 in hemoglobin-adjusted percent predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) achieved statistical significance, with a change...
$Savara(SVRA.US$ The company released results from Phase 3 IMPALA-2 trial of molgramostim 300 mcg administered once daily by inhalation with a matching placebo for autoimmune pulmonary alveolar proteinosis (aPAP).
No comment yet
zezzzo : You will see the 7$
TrytosaveabitOP zezzzo: Yup at some point! Would be nice sooner than later. And for it to actually hold longer than a day when it does get there! Hehehe. GL to ya
Ebere : Indeed, Its a Miracle!